Stanol esters as a dietary adjunct to cholesterol-lowering therapies

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Results of clinical trials confirm the efficacy and safety of statins for cholesterol lowering and open the door to new approaches to reducing low-density lipoprotein (LDL) cholesterol concentrations. Statins inhibit cholesterol synthesis, reduce hepatic cholesterol, enhance expression of LDL receptors and lower serum LDL cholesterol levels. Another way to increase LDL receptors is to inhibit cholesterol absorption, which reduces serum LDL cholesterol about one-half of that obtained by statin therapy. Although different agents inhibit cholesterol absorption (e.g. Olestra, neomycin, surformer [AOMA], acyl coenzyme A acyltransferase inhibitors, microsomal lipid transfer protein inhibitors, plant sterols and stanols), the latter are the most practical for widespread use. Stanols act entirely within the gastrointestinal tract, a feature that greatly increases their safety. Consequently, they are a useful adjunct to dietary therapy for LDL cholesterol lowering. Stanol esters have other characteristics of an ideal dietary adjunct for cholesterol lowering. They are well tolerated and seemingly are free from side-effects. Their potential utility as a dietary adjunct for lowering LDL cholesterol is considered in the context of preventive strategies, both secondary and short- and long-term primary prevention, in high-risk and low-risk persons.

Original languageEnglish (US)
JournalEuropean Heart Journal, Supplement
Volume1
Issue numberS
StatePublished - 1999

Fingerprint

LDL Cholesterol
Esters
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
LDL Receptors
Dietary Cholesterol
Therapeutics
Safety
Acyltransferases
Phytosterols
Acyl Coenzyme A
Neomycin
Primary Prevention
Serum
Gastrointestinal Tract
Clinical Trials
Liver

Keywords

  • Cholesterol absorption
  • Primary prevention
  • Secondary prevention
  • Stanol esters
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Stanol esters as a dietary adjunct to cholesterol-lowering therapies. / Grundy, Scott M.

In: European Heart Journal, Supplement, Vol. 1, No. S, 1999.

Research output: Contribution to journalArticle

@article{441965ef12da4ddd8b52a7e106c47021,
title = "Stanol esters as a dietary adjunct to cholesterol-lowering therapies",
abstract = "Results of clinical trials confirm the efficacy and safety of statins for cholesterol lowering and open the door to new approaches to reducing low-density lipoprotein (LDL) cholesterol concentrations. Statins inhibit cholesterol synthesis, reduce hepatic cholesterol, enhance expression of LDL receptors and lower serum LDL cholesterol levels. Another way to increase LDL receptors is to inhibit cholesterol absorption, which reduces serum LDL cholesterol about one-half of that obtained by statin therapy. Although different agents inhibit cholesterol absorption (e.g. Olestra, neomycin, surformer [AOMA], acyl coenzyme A acyltransferase inhibitors, microsomal lipid transfer protein inhibitors, plant sterols and stanols), the latter are the most practical for widespread use. Stanols act entirely within the gastrointestinal tract, a feature that greatly increases their safety. Consequently, they are a useful adjunct to dietary therapy for LDL cholesterol lowering. Stanol esters have other characteristics of an ideal dietary adjunct for cholesterol lowering. They are well tolerated and seemingly are free from side-effects. Their potential utility as a dietary adjunct for lowering LDL cholesterol is considered in the context of preventive strategies, both secondary and short- and long-term primary prevention, in high-risk and low-risk persons.",
keywords = "Cholesterol absorption, Primary prevention, Secondary prevention, Stanol esters, Statins",
author = "Grundy, {Scott M}",
year = "1999",
language = "English (US)",
volume = "1",
journal = "European Heart Journal, Supplement",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "S",

}

TY - JOUR

T1 - Stanol esters as a dietary adjunct to cholesterol-lowering therapies

AU - Grundy, Scott M

PY - 1999

Y1 - 1999

N2 - Results of clinical trials confirm the efficacy and safety of statins for cholesterol lowering and open the door to new approaches to reducing low-density lipoprotein (LDL) cholesterol concentrations. Statins inhibit cholesterol synthesis, reduce hepatic cholesterol, enhance expression of LDL receptors and lower serum LDL cholesterol levels. Another way to increase LDL receptors is to inhibit cholesterol absorption, which reduces serum LDL cholesterol about one-half of that obtained by statin therapy. Although different agents inhibit cholesterol absorption (e.g. Olestra, neomycin, surformer [AOMA], acyl coenzyme A acyltransferase inhibitors, microsomal lipid transfer protein inhibitors, plant sterols and stanols), the latter are the most practical for widespread use. Stanols act entirely within the gastrointestinal tract, a feature that greatly increases their safety. Consequently, they are a useful adjunct to dietary therapy for LDL cholesterol lowering. Stanol esters have other characteristics of an ideal dietary adjunct for cholesterol lowering. They are well tolerated and seemingly are free from side-effects. Their potential utility as a dietary adjunct for lowering LDL cholesterol is considered in the context of preventive strategies, both secondary and short- and long-term primary prevention, in high-risk and low-risk persons.

AB - Results of clinical trials confirm the efficacy and safety of statins for cholesterol lowering and open the door to new approaches to reducing low-density lipoprotein (LDL) cholesterol concentrations. Statins inhibit cholesterol synthesis, reduce hepatic cholesterol, enhance expression of LDL receptors and lower serum LDL cholesterol levels. Another way to increase LDL receptors is to inhibit cholesterol absorption, which reduces serum LDL cholesterol about one-half of that obtained by statin therapy. Although different agents inhibit cholesterol absorption (e.g. Olestra, neomycin, surformer [AOMA], acyl coenzyme A acyltransferase inhibitors, microsomal lipid transfer protein inhibitors, plant sterols and stanols), the latter are the most practical for widespread use. Stanols act entirely within the gastrointestinal tract, a feature that greatly increases their safety. Consequently, they are a useful adjunct to dietary therapy for LDL cholesterol lowering. Stanol esters have other characteristics of an ideal dietary adjunct for cholesterol lowering. They are well tolerated and seemingly are free from side-effects. Their potential utility as a dietary adjunct for lowering LDL cholesterol is considered in the context of preventive strategies, both secondary and short- and long-term primary prevention, in high-risk and low-risk persons.

KW - Cholesterol absorption

KW - Primary prevention

KW - Secondary prevention

KW - Stanol esters

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=0032698124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032698124&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032698124

VL - 1

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

SN - 1520-765X

IS - S

ER -